This clinical trial is focused on studying certain blood-related diseases and the effects of a treatment known as *CAR-T cell therapy*. This therapy involves using specially modified cells to target and fight cancer cells. The study will use several medications, including *Tecartus*, *Abecma*, *Kymriah*, *Breyanzi*, and *Yescarta*. These medications are all forms of *CAR-T cell therapy*, which is a type of treatment that uses the patient’s own immune cells, modified in a lab, to attack cancer cells. Another medication, *Gadovist*, will be used as a contrast agent during imaging tests to help visualize the body’s internal structures.

The purpose of the study is to understand how tiny particles called *extracellular vesicles* change over time when patients receive *CAR-T cell therapy*. These vesicles are small structures released by cells that can carry signals and materials between cells. The study will also look at a condition called *Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)*, which can occur during this type of treatment. ICANS is a temporary condition that affects the nervous system and can cause symptoms like confusion or difficulty speaking.

Participants in the study will receive *CAR-T cell therapy* and will be monitored over time to see how their *extracellular vesicles* change before and after treatment. The study will also examine how these changes relate to the presence of *ICANS* and other factors like cytokine levels, which are proteins that help control the immune system. Additionally, the study will explore the relationship between these vesicles and any neurological symptoms or sleep apnea that may occur. Imaging tests, such as *MRI*, will be used to observe any changes in the brain before and after treatment. The study aims to provide a better understanding of how *CAR-T cell therapy* affects the body and to improve the management of side effects like *ICANS*.